Terazosin Capsule
Product Images NDC 70518-4545

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Terazosin (NDC 70518-4545). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Remedy_label (Remedy Label)

Remedy_label (Remedy Label)
Description: Terazosin Capsule 2mg is a medication repackaged by RemedyRepack Inc. The capsules are white TE2 in color and should be kept protected from light and moisture. Manufactured by Bionpharma Inc., the usual dosage instructions are provided in the insert. It is important to store the capsules at a temperature between 20-25°C (68-77°F) with excursions permitted to 15-30°C (59-86°F). Remember to keep this medication out of the reach of children.*
FDA Label Image

Image Description (Figure 01)

Image Description (Figure 01)
This is a comparison of the mean change in total symptom scores and mean increase in peak flow rate from baseline in a study involving a placebo group and a group receiving terazosin medication. The results are shown for different time points up to 3 months.*
FDA Label Image

Image Description (Figure 02)

Image Description (Figure 02)
This is a description of a long-term, open-label, non-placebo controlled study involving 494 participants. The figure displays the mean change in total symptom score from baseline over a period of 30 months, with data points at months 0, 3, 6, 9, 12, 15, 18, 21, 24, 27, and 30.*
FDA Label Image

Image Description (Figure 03)

Image Description (Figure 03)
The text represents a graph showing the mean change in peak flow rate from baseline over a long-term, open-label, non-placebo controlled study. This study involved 494 participants, and the data is presented monthly over a period of 30 months. The graph provides insights into how the peak flow rate changes over time in the study population.*
FDA Label Image

Image Description (Structure001)

Image Description (Structure001)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.